Colposcopy Referral and CIN3+Risk of Human Papillomavirus Genotyping Strategies in Cervical Cancer Screening

被引:2
|
作者
Kroon, Kelsi R. [1 ,2 ]
Bogaards, Johannes A. [1 ,2 ]
Heideman, Danielle A. M. [3 ,4 ,5 ]
Meijer, Chris J. L. M. [3 ,4 ]
Berkhof, Johannes [1 ,2 ]
机构
[1] Vrije Univ Amsterdam, Epidemiol & Data Sci, Amsterdam UMC, De Boelelaan 1089a, NL-1081 HV Amsterdam, Netherlands
[2] Amsterdam Publ Hlth Res Inst, Methodol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Pathol, Amsterdam UMC, Amsterdam, Netherlands
[4] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands
基金
欧盟地平线“2020”;
关键词
RISK HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; BASE-LINE; CYTOLOGY; WOMEN; IMPLEMENTATION; GUIDELINES; POBASCAM;
D O I
10.1158/1055-9965.EPI-24-0046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: High-risk human papillomavirus (hrHPV)-based cervical cancer screening in the Netherlands led to a substantial increase in number of colposcopy referrals and low-grade lesions detected. Genotyping strategies may be employed to lower the screening-related burden.Methods: We evaluated 14 triage strategies with genotyping (HPV16/18 or HPV16/18/31/33/45/52/58) for hrHPV-positive borderlineormilddyskaryosis (BMD)ornormal cytology,usingdata from a population-based hrHPV-based screening trial with 5-year interval (POBASCAM). We considered colposcopy referral at baseline, after 6-month repeat cytology and after 5-year hrHPV testing. Performance was evaluated by one-round positive and negative predictive value (PPVandNPV) for CIN3+ and by two-roundcolposcopy referral rate. To identify efficient strategies, they were ordered by the one-round colposcopy referral rate. Adjacent strategies were compared by the marginal PPV for detecting one additional CIN3+ (mPPV).Results: The most conservative strategy (repeat cytology after BMD and HPV16/18/31/33/45/52/58-positive normal cytology, next round otherwise) yielded an mPPV of 28%, NPV of 98.2%, and two-round colposcopy referral rate of 47.2%. Adding direct referral after BMD or genotype-positive BMD yielded an mPPV <= 8.2%, NPV >= 98.5% and an increase in colposcopy referral rate of 1.9% to 6.5%. Adding direct referral after HPV16/18-positive normal cytology yielded an mPPV <= 3.5%, NPV >= 99.5% and an increase in colposcopy referral rate of 13.9%.Conclusions: Direct colposcopy referral of women with BMD or normal cytology is unlikely to be efficient, but genotype-guided direct referral after BMD may be considered because the increase in colposcopies is limited.Impact: hrHPV screening programs can become very efficient when immediate colposcopy referral is limited to women at highest CIN3+ risk. See related In the Spotlight, p. 979Impact: hrHPV screening programs can become very efficient when immediate colposcopy referral is limited to women at highest CIN3+ risk. See related In the Spotlight, p. 979
引用
收藏
页码:1037 / 1045
页数:9
相关论文
共 50 条
  • [21] Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population
    Wong, Oscar G. W.
    Ng, Idy F. Y.
    Tsun, Obe K. L.
    Pang, Herbert H.
    Ip, Philip P. C.
    Cheung, Annie N. Y.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2019, 57 (12)
  • [22] Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy
    Porras, Carolina
    Wentzensen, Nicolas
    Rodriguez, Ana C.
    Morales, Jorge
    Burk, Robert D.
    Alfaro, Mario
    Hutchinson, Martha
    Herrero, Rolando
    Hildesheim, Allan
    Sherman, Mark E.
    Wacholder, Sholom
    Solomon, Diane
    Schiffman, Mark
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (08) : 1879 - 1887
  • [23] Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening
    Rebolj, M.
    Njor, S.
    Lynge, E.
    Preisler, S.
    Ejegod, D.
    Rygaard, C.
    Bonde, J.
    CYTOPATHOLOGY, 2017, 28 (05) : 419 - 428
  • [24] Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing
    Green, Leonardo I.
    Mathews, Christopher S.
    Waller, Jo
    Kitchener, Henry
    Rebolj, Matejka
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (08) : 1850 - 1857
  • [25] Human papillomavirus test with cytology triage in organized screening for cervical cancer
    Veijalainen, Olga
    Kares, Saara
    Kujala, Paula
    Tirkkonen, Mika
    Vuento, Risto
    Kholova, Ivana
    Luukkaala, Tiina
    Osuala, Veronika
    Maenpaa, Johanna
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2016, 95 (11) : 1220 - 1227
  • [26] Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: a retrospective population-based cohort study
    Dong, Binhua
    Zou, Huachun
    Mao, Xiaodan
    Su, Yingying
    Gao, Hangjing
    Xie, Fang
    Lv, Yuchun
    Chen, Yaojia
    Kang, Yafang
    Xue, Huifeng
    Pan, Diling
    Sun, Pengming
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [27] Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China
    Zhang, Yanru
    Wang, Yueyun
    Liu, Li
    Guo, Chun
    Liu, Zhihua
    Nie, Shaofa
    ONCOTARGET, 2016, 7 (38) : 62411 - 62424
  • [28] Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme
    Nygard, Mari
    Roysland, Kjetil
    Campbell, Suzanne
    Dillner, Joakim
    BMJ OPEN, 2014, 4 (01):
  • [29] Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment
    Stuebs, Frederik A.
    Koch, Martin C.
    Dietl, Anna K.
    Adler, Werner
    Geppert, Carol
    Hartmann, Arndt
    Knoell, Antje
    Beckmann, Matthias W.
    Mehlhorn, Grit
    Schulmeyer, Carla E.
    Gass, Paul
    DIAGNOSTICS, 2022, 12 (07)
  • [30] Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies
    Liu, Ying
    Ai, Hao
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (06):